×
Cytometric analysis of patients with COVID-19: what is changed in the second wave?
https://doi.org/10.1186/s12967-021-03072-1 10.1056/NEJMcp2009249 10.1056/NEJMcp2009575 10.1016/j.lfs.2020.118355 10.3389/fimmu.2020.607069 10.1183/13993003.02182-2020 10.1016/j.intimp.2021.107586 10.3389/fimmu.2021.655934 10.1371/journal.ppat.1009448 10.1016/j.it.2020.11.002 10.3390/ijerph17238708 10.1007/s40520-020-01764-0 10.1080/23744235.2021.1884745 10.1056/NEJMoa2021436 10.1007/s40264-020-00976-7 10.1515/cclm-2020-0442 10.3390/diagnostics11020288 10.1097/CCM.0000000000004741 10.1016/S1473-3099(20)30483-7 10.1038/s41577-020-00421-x 10.7150/ijbs.47652 10.3389/fimmu.2018.00302 10.1182/bloodadvances.2020002650 10.1007/s40618-021-01565-w 10.3389/fpubh.2021.664108 10.1002/JLB.4COVCRA0820-481RRR 10.1196/annals.1321.010 10.1016/j.jmii.2019.10.001 10.3389/fimmu.2020.556579 10.3389/fimmu.2020.00827 10.1038/s41423-020-0402-2 10.1111/imm.13262 10.4049/jimmunol.2000554 10.1111/bcp.14437 10.1038/s41577-020-0328-z 10.1111/bph.15452 10.2340/00015555-3816 10.1111/bjd.17580 10.1073/pnas.2005615117
Journal of Translational Medicine; Scalia G, Raia M et. al.

Sep 25th, 2021 - Coronavirus disease 2019 (COVID-19) pandemic had a 1st wave in Europe from March to May 2020 and a 2nd wave since September 2020. We previously studied 35 hospitalized COVID-19 patients of the 1st wave demonstrating a cytokine storm and the exhaustion of most lymphocyte subpopulations. Herein, we describe the results obtained from COVID-19 patients of the 2nd wave. We analyzed interleukin (IL)-...

Antibody and cellular therapies for treatment of covid-19: a living systematic review a...
https://doi.org/10.1136/bmj.n2231
BMJ (Clinical Research Ed.); Siemieniuk RA, Bartoszko JJ et. al.

Sep 25th, 2021 - To evaluate the efficacy and safety of antiviral antibody therapies and blood products for the treatment of novel coronavirus disease 2019 (covid-19). Living systematic review and network meta-analysis, with pairwise meta-analysis for outcomes with insufficient data. WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature, and six Chinese databases (up to 21 Jul...

SARS-CoV-2 mucosal antibody development and persistence and their relation to viral loa...
https://doi.org/10.1038/s41467-021-25949-x 10.1016/j.cmi.2020.04.040 10.1056/NEJMe2009758 10.1056/NEJMoa2008457 10.3201/eid2702.203517 10.1038/s41467-020-19545-8 10.1056/NEJMoa2034577 10.1038/s41586-020-2639-4 10.1128/JVI.00647-20 10.1172/jci.insight.142386 10.4049/jimmunol.180.2.948 10.1128/JVI.80.8.4079-4087.2006 10.1038/s41591-020-0868-6 10.1016/j.cell.2020.05.042 10.1038/s41564-020-00813-8 10.1371/journal.pone.0240205 10.1093/infdis/jis033 10.1016/j.jcv.2014.04.017 10.1038/s41467-020-16256-y 10.1093/infdis/jiaa479 10.18637/jss.v082.i13
Nature Communications; Fröberg J, Gillard J et. al.

Sep 25th, 2021 - Although serological studies have shown that antibodies against SARS-CoV-2 play an important role in protection against (re)infection, the dynamics of mucosal antibodies during primary infection and their potential impact on viral load and the resolution of disease symptoms remain unclear. During the first pandemic wave, we assessed the longitudinal nasal antibody response in index cases with m...

Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after ...
https://doi.org/10.1136/bmjopen-2021-053791
BMJ Open; Khan SMS, Qurieshi MA et. al.

Sep 25th, 2021 - We designed a population-based survey in Kashmir to estimate the seroprevalence of SARS-CoV-2-specific IgG antibodies in the general population aged 18 years and above. The survey was conducted among 110 villages and urban wards across 10 districts in Kashmir from 17 October 2020 to 4 November 2020. Individuals aged 18 years and above were eligible to be included in the survey. Serum samples we...

Limited Protection of Inactivated SARS-CoV-2 Vaccine against Wuhan Strain and Variants ...
https://doi.org/10.3201/eid2712.211772
Emerging Infectious Diseases; Hunsawong T, Fernandez S et. al.

Sep 25th, 2021 - In vitro determination of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies induced in serum samples from recipients of the CoronaVac vaccine showed a short protection period against the original virus strain and limited protection against variants of concern. These data provide support for vaccine boosters, especially variants of concern circulate.

A Daily Pill to Treat COVID Could Be Just Months Away, Scientists Say
https://www.medscape.com/viewarticle/959705

Sep 24th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room. When her husband, Joe, 4...

Differentiation of immortalized human multi-lineage progenitor to alveolar type 2-like ...
https://doi.org/10.1016/j.jcyt.2021.07.017
Cytotherapy Collins DP, Osborn MJ et. al.

Sep 24th, 2021 - Along with the nasal epithelium, the lung epithelium is a portal of entry for sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and many other respiratory viruses. In the case of SARS-CoV-2, the virus surface spike proteins bind to the angiotensin-converting enzyme 2 (ACE-2) receptor to facilitate entry into the respiratory epithelium. Alveolar type 2 (AT2) cells are committed respir...

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian gold...
https://doi.org/10.1038/s41467-021-25480-z 10.1038/s41586-020-2548-6 10.1038/s41586-020-2571-7 10.1038/s41586-020-2380-z 10.1016/j.cell.2020.05.025 10.1126/science.abc7520 10.3389/fimmu.2021.690742 10.1038/s41594-020-0469-6 10.1016/j.cell.2020.05.047 10.1038/s41467-020-19204-y 10.1038/s41467-020-18174-5 10.1038/s41598-021-82833-w 10.1128/JVI.03178-13 10.1371/journal.pone.0069495 10.1016/j.nucmedbio.2015.03.003 10.1074/jbc.M007734200 10.1128/AAC.01802-15 10.1371/journal.pmed.0030237 10.1038/s41594-020-0469-6 10.1016/j.chom.2020.06.010 10.1126/science.abd2321 10.1371/journal.ppat.1009352 10.1038/s41594-020-0480-y 10.1002/1873-3468.14076 10.1016/j.chom.2020.11.007 10.1126/science.abb2507 10.1016/j.cell.2020.02.058 10.1371/journal.pone.0017665 10.1073/pnas.2018975117 10.1038/s41586-020-2342-5 10.1128/JVI.79.1.503-511.2005 10.1126/science.abb7269 10.1016/j.cell.2020.04.031 10.1016/j.pharmthera.2016.06.012 10.1038/s41598-020-79036-0 10.1007/978-1-59745-196-3_16 10.1007/978-1-62703-764-8_15 10.1107/S0907444905001617 10.1107/S0907444903028956 10.1107/S0907444910045749 10.1107/S0907444904019158 10.1107/S0907444911001314 10.1107/S2052252514009324 10.1093/nar/gkm216 10.1016/S0076-6879(03)74014-2 10.1107/S0021889805038987 10.1107/S2059798319011471 10.1002/pro.3330 10.1107/S2059798318009324 10.5694/mja2.50569 10.1038/s41596-021-00536-y 10.1038/s41586-020-2196-x 10.1093/infdis/jiaa507
Nature Communications; Huo J, Mikolajek H et. al.

Sep 24th, 2021 - SARS-CoV-2 remains a global threat to human health particularly as escape mutants emerge. There is an unmet need for effective treatments against COVID-19 for which neutralizing single domain antibodies (nanobodies) have significant potential. Their small size and stability mean that nanobodies are compatible with respiratory administration. We report four nanobodies (C5, H3, C1, F2) engineered...

Toward a universal influenza virus vaccine: Some cytokines may fulfill the request.
https://doi.org/10.1016/j.cyto.2021.155703
Cytokine Taheri M, Nemattalab M et. al.

Sep 24th, 2021 - The influenza virus annually causes widespread damages to the health and economy of the global community. Vaccination is currently the most crucial strategy in reducing the number of patients. Genetic variations, the high diversity of pandemic viruses, and zoonoses make it challenging to select suitable strains for annual vaccine production. If new pandemic viruses emerge, it will take a long t...

Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal A...
https://doi.org/10.1016/j.clinthera.2021.08.009
Clinical Therapeutics; Kim JY, Jang YR et. al.

Sep 24th, 2021 - Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal antibody, was examined in 2 randomized, double-blind, placebo-controlled, single ascending dose, Phase I studies. In study 1.1, healthy adults were sequentially enrolled to receive CT-P59 10, 20, 40, or 80 mg/kg or placebo. In study 1.2, a...

Frontline Bevacizumab/Erlotinib Continues to Impress in EGFR-Mutated NSCLC
https://www.onclive.com/view/frontline-bevacizumab-erlotinib-continues-to-impress-in-egfr-mutated-nsclc

Sep 23rd, 2021 - The addition of bevacizumab (Avastin) to erlotinib (Tarceva) continued to provide a significant progression-free survival (PFS) benefit over erlotinib alone when used in the frontline treatment of patients with EGFR-mutated, nonsquamous non–small cell lung cancer (NSCLC), according to data from the final analysis of the phase 3 BEVERLY trial (NCT02633189).1 The data, which were virtually pre...

No antibody response in cutaneous manifestations associated with COVID-19: an observati...
https://doi.org/10.1111/dth.15142
Dermatologic Therapy; García-Gil MF, Monte-Serrano J et. al.

Sep 23rd, 2021 - The microbiological diagnosis of skin lesions related to COVID-19 is not well known. Perform a microbiological diagnosis in COVID19-related cutaneous manifestations. A cross-sectional study was performed with 64 patients with cutaneous manifestations associated with COVID-19 who underwent serological and nasopharyngeal RT-PCR for SARS-CoV-2. Out of the 64 patients, 6 patients had positive RT-PC...

Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants.
https://doi.org/10.1128/JVI.01313-21
Journal of Virology; Choi A, Koch M et. al.

Sep 23rd, 2021 - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variant...

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody co...
https://doi.org/10.1038/s41564-021-00972-2 10.1016/j.cell.2020.02.052 10.1038/s41564-020-0688-y 10.1128/mSphere.00160-20 10.1073/pnas.1708727114 10.1038/s41598-020-73491-5 10.1038/s41591-020-0897-1 10.1016/j.cell.2020.09.037 10.1126/science.abc5902 10.1016/j.cell.2020.05.025 10.1126/science.abd0827 10.1038/s41586-020-2380-z 10.1038/s41586-020-2571-7 10.1038/s41586-020-2456-9 10.1126/science.abc7520 10.1038/s41586-020-2381-y 10.4049/jimmunol.171.9.4680 10.1038/s41586-020-2548-6 10.1038/s41586-020-2772-0 10.1126/science.abb2507 10.1038/s41594-020-0468-7 10.1038/s41591-020-0998-x 10.1038/s41467-021-24435-8 10.1126/science.abe3354 10.1016/j.cell.2020.06.044 10.1093/nar/gki385 10.1016/j.cell.2021.02.032 10.1038/s41586-019-0934-8 10.1016/j.chom.2020.11.007 10.1016/j.cell.2020.08.012 10.1016/j.chom.2020.06.021 10.1099/jgv.0.001481 10.1073/pnas.2025601118 10.1126/science.abe2402 10.1016/j.cell.2020.07.012 10.15585/mmwr.mm7003e2 10.2807/1560-7917.ES.2020.26.1.2002106 10.1038/s41586-021-03402-9 10.1128/JVI.00119-21 10.1038/s41586-021-03693-y 10.1016/j.cell.2021.04.025 10.1038/s41591-021-01294-w 10.1016/j.chom.2021.01.014 10.1016/j.chom.2021.02.003 10.1038/s41591-021-01285-x 10.1073/pnas.2103154118 10.1038/s41586-021-03471-w 10.1016/j.chom.2021.04.007 10.1038/s41586-021-03398-2 10.1038/s41586-021-03324-6 10.1038/s41586-020-2012-7 10.4049/jimmunol.180.5.3279 10.1126/science.1207532 10.1016/j.cell.2015.05.007 10.1073/pnas.0308527100 10.1126/science.aab1253 10.1016/j.cell.2016.06.043 10.1038/nature13764 10.1038/nsmb.1566 10.4049/jimmunol.1402835 10.1172/jci.insight.92872 10.1073/pnas.1114927109 10.1126/science.abd2321 10.1016/j.chom.2020.09.002 10.1084/jem.20151960 10.1016/j.cell.2021.01.037 10.1107/S0907444909047337 10.1107/S0907444910045749 10.1107/S0021889807021206 10.1107/S0907444909052925 10.1107/S0907444904019158 10.1126/science.abf9302 10.1073/pnas.1804015115 10.1126/science.abd0826 10.1038/s41586-020-2895-3 10.1016/j.chom.2020.04.004 10.1038/msb.2011.75 10.1186/1471-2105-5-113 10.1101/gr.849004
Nature Microbiology; Dong J, Zost SJ et. al.

Sep 23rd, 2021 - Understanding the molecular basis for immune recognition of SARS-CoV-2 spike glycoprotein antigenic sites will inform the development of improved therapeutics. We determined the structures of two human monoclonal antibodies-AZD8895 and AZD1061-which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor-binding domain (RBD) of SARS-CoV-2 to define the gene...

Impact of rituximab on COVID-19 outcomes.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455155
Annals of Hematology; Levavi H, Lancman G et. al.

Sep 23rd, 2021 - Rituximab is associated with prolonged B-cell depletion and secondary hypogammaglobulinemia and is associated with a dampened humoral response and increased infectious complications. To describe the potential impact of prior rituximab therapy on clinical outcomes from SARS-CoV-2 infection and development of COVID-19 antibodies, we conducted a retrospective study of adults across the Mount Sinai...

Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in...
https://doi.org/10.1371/journal.ppat.1009701
PLoS Pathogens; Rosati M, Agarwal M et. al.

Sep 23rd, 2021 - The speed of development, versatility and efficacy of mRNA-based vaccines have been amply demonstrated in the case of SARS-CoV-2. DNA vaccines represent an important alternative since they induce both humoral and cellular immune responses in animal models and in human trials. We tested the immunogenicity and protective efficacy of DNA-based vaccine regimens expressing different prefusion-stabil...

Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipie...
https://doi.org/10.1111/ajt.16854
American Journal of Transplantation : Official Journal Of... Crespo M, Barrilado-Jackson A et. al.

Sep 23rd, 2021 - Studies are urgently needed to characterize immunogenicity, efficacy, and safety of SARS-CoV-2 mRNA vaccines in kidney transplant (KT) recipients, excluded from major clinical trials. Complex ELISPOT and other cellular response techniques have been applied, but simpler tools are needed. An easy-to-use real-world monitoring of SARS-CoV-2 IgG antibodies against the Spike protein and QuantiFERON® ...

Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine ...
https://doi.org/10.1093/cid/ciab845
Clinical Infectious Diseases : an Official Publication Of... Zhu F, Jin P et. al.

Sep 23rd, 2021 - We assessed the safety and immunogenicity of a recombinant adenovirus type-5 (Ad5)-vectored COVID-19 vaccine with homologous prime-boost regimens in healthy participants aged 6 years and above. In this randomised, double-blind, placebo-controlled trial, participants received low-dose vaccine, middle-dose vaccine or placebo. Prime-booster regimens were given intramuscularly 56 days apart. ELISA ...

Intensity of mycophenolate mofetil treatment is associated with an impaired immune resp...
https://doi.org/10.1111/ajt.16851
American Journal of Transplantation : Official Journal Of... Kantauskaite M, Müller L et. al.

Sep 23rd, 2021 - Kidney transplant recipients (KTRs) are extremely vulnerable to SARS-CoV-2 infection and show an impaired immune response to SARS-CoV-2 vaccination. We analyzed factors related to vaccination efficiency in KTRs. In a multicenter prospective observational study (NCT04743947), IgG antibodies levels against SARS-CoV-2 spike S1 subunit and their neutralization capacity after SARS-CoV-2 vaccination ...

Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent ...
https://doi.org/10.1111/trf.16685
Transfusion Brox R, Achenbach S et. al.

Sep 22nd, 2021 - Convalescent plasma has emerged as a potential specific treatment for coronavirus disease 2019 (COVID-19), since it contains severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. Several studies are currently investigating the efficacy of convalescent plasma for treatment of COVID-19, with a focus on neutralizing antibodies. However, there is little information on whether con...